Health Care & Life Sciences » Biotechnology | Newron Pharmaceuticals

Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A.
Stock Exchange SIX Swiss Exchange
EPS
CHF0.97
Market Cap
CHF113.32 M
Shares Outstanding
17.85 M
Public Float
13.99 M

Profile

Address
via Ludovico Ariosto 21
Bresso Milan 20091
Italy
Employees -
Website http://www.newron.com
Updated 07/08/2019
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Its products include Xadago for Parkinson's disease; sarizotan for patients with Rett syndrome; and ralfinamide for patients with rare pain indications. The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Financials

View All

Stefan Weber
Chief Executive Officer, Director & IR Contact
Ulrich Köstlin
Non-Executive Chairman